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Background: Ovarian cancer (OvCa) is the most lethal gynecological malignancy. The emergence of high-throughput
technologies, such as mass spectrometry, has allowed for a paradigm shift in the way we search for novel biomarkers.
Urine-based peptidomic profiling is a novel approach that may result in the discovery of noninvasive biomarkers for
diagnosing patients with OvCa. In this study, the peptidome of urine from 6 ovarian cancer patients and 6 healthy
controls was deciphered.
Results: Urine samples underwent ultrafiltration and the filtrate was subjected to solid phase extraction, followed by
fractionation using strong cation exchange chromatography. These fractions were analyzed using an Orbitrap mass
spectrometer. Over 4600 unique endogenous urine peptides arising from 713 proteins were catalogued, representing
the largest urine peptidome reported to date. Each specimen was processed in triplicate and reproducibility at the protein
(69-76%) and peptide (58-63%) levels were noted. More importantly, over 3100 unique peptides were detected solely in
OvCa specimens. One such promising biomarker was leucine-rich alpha-2-glycoprotein (LRG1), where multiple peptides
were found in all urines from OvCa patients, but only one peptide was found in one healthy control urine sample.
Conclusions: Mining the urine peptidome may yield highly promising novel OvCa biomarkers.
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Ovarian cancer (OvCa) is the fifth largest killer and the
most lethal gynecological malignancy, accounting for
approximately 3% of all new cancer cases in 2012 [1].
The reason for the high fatality rate is that the disease is
often diagnosed in advanced stages (stage III and IV)
when the cancer has metastasized to other organs. The
5-year survival rate for patients with advanced disease is
10-30%, whereas those diagnosed in earlier stages have a
5-year survival rate that exceeds 90% [2]. Carbohydrate
antigen 125 (CA125) is the most widely used and clinically
accepted serum marker for OvCa. Despite its widespread
use for monitoring therapeutic response in OvCa patients,
CA125 is a poor marker for early diagnosis due to* Correspondence: vathany.kulasingam@uhn.ca
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reproduction in any medium, provided the orfrequent false positive and false negative results. Other
markers have shown utility in the detection of OvCa such
as HE4, osteopontin, CA 15–3 and CA19-9; however, none
of these proteins have shown efficacy for early detection of
OvCa [3]. For these reasons, efforts to discover novel OvCa
biomarkers continue to date.
The investigation of the peptidome, or the low-mole
cular weight proteome, of biological fluids relevant to
OvCa is an emerging field. It is hypothesized that meta-
bolic activity increases in tandem with the progression of
malignancy and consequently, protease activity increases
as well. Thus, endogenous peptides are generated, some of
which may be secreted into the surrounding environment
where they can theoretically be detected and used to moni-
tor disease. Furthermore, the progression of malignancy is
also associated with the degradation of adhesion and cell-
to-cell junction proteins and this may also be another
source of endogenous peptides with diagnostic potential. It
is well known that peptides play complex regulatory roles
in many biological processes, such as intercellular signal-
ing [4-9]. Current proteomic approaches to biomarkertd. This is an Open Access article distributed under the terms of the Creative
ommons.org/licenses/by/2.0), which permits unrestricted use, distribution, and
iginal work is properly credited.
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make it possible to delineate the endogenous peptidomes
of various bodily fluids.
One such biofluid that may be suited for OvCa diagnosis
is urine. The analysis of urine plays a central role in clin-
ical diagnostics due to its availability in almost all patients
and its simplicity of collection non-invasively. Urine can
be collected in large volumes and its excretion is a normal
and necessary function. This is in contrast to other bodily
fluids such as blood, where collection is more invasive,
prone to collection artifacts and where the activation of
proteases (especially the coagulation cascade) generates
many proteolytic breakdown products [10]. Urine is
known to be relatively stable, likely due to the fact that it
is ‘stored’ for hours in the bladder and therefore, proteo-
lytic degradation may be complete at the time of voiding
[11]. Urine has also been shown to contain a diverse set of
proteins/peptides, where approximately 70% of all urinary
proteins originate from the kidney, and 30% are derived
from the plasma, making it an attractive fluid for bio-
marker discovery [11].
Although peptidomics is still in its infancy, there have
already been a few studies that have reported on the utility
of peptides for OvCa diagnostics. Fredolini et al. reported
59 peptide markers that were unique to OvCa patients
compared to patients with benign gynecologic conditions
[12]. On the contrary, Timms et al. recently reported that
MALDI MS peptide profiling was unable to accurately
diagnose OvCa from healthy controls, though the en-
dogenous peptides could provide some diagnostic insight
[13]. Needless to say, greater characterization of the
endogenous peptidome of various biospecimens related to
OvCa is needed to truly assess whether or not peptide-
based biomarkers are clinically useful. Since the first
serum peptidomic study of OvCa [14], multiple studies in
several body fluids have pointed out a wide array of low-
molecular-weight proteins and peptides with high disease-
specific information for different types of cancer [15,16].
In this study, we were able to identify several thousands
of endogenous peptides in the urine of OvCa patients and
healthy controls. Our work represents the largest urine
peptidomic study to date for any disease type. In addition,
there are no studies in the literature looking at urine pep-
tidomics and OvCa. This makes our peptidomics study of
major importance in the pursuit of early diagnostic bio-
markers for this malignancy. A number of our identified
peptides may have value as candidate OvCa biomarkers
and could be targeted for further validation in the future.
Results and discussion
Optimization of sample preparation for urine peptidome
identification
To perform an in-depth peptidomic analysis on urine, it
is essential to have a procedure that is robust and comprehensive. To accomplish this, each step of the proced-
ure was examined carefully and alternative strategies
were applied before selecting the “optimal” procedure that
yielded the greatest number of peptides reproducibly.
Method development and evaluation were performed
using the second morning urine of a single donor, spiked
with known concentrations of synthetic heavy peptides
from five proteins [IL8 (3 peptides), VEGF (3 peptides),
IGFBP2 (4 peptides), HER2 (4 peptides) and VIP (1 pep-
tide)] at known concentrations (ranging from 2–1000
pmol). Methods were considered to be superior if more
peptides were identified (both endogenous and spiked).
One of the first steps considered when performing pep-
tidomic analysis on urine was the low protein content of
urine, in relation to other fluids such as serum. As a result,
it was essential to examine methods for urine concentra-
tion. Centrifugal filter units are inexpensive, easy to use
and can rapidly separate the protein and peptide compo-
nents. In this study, the Millipore Amicon Ultracel con-
centrators (5 and 10 kDa MWCO) and Sartorius Stedium
Vivaspin 20 mL concentrators (5 and 10 kDa MWCO)
were evaluated and a greater number of peptides were
identified with the Vivaspin 20 mL 10 kDa MWCO unit
(data not shown). Using this centrifugal filter, 10–30 mL
of filtrate was required prior to further treatment and
injection on the mass spectrometer. Next, the most appro-
priate solid-phase extraction column was selected by
examining two different cartridges: C8 (Varian SPEC) and
Oasis HLB. The Oasis cartridges were able to identify
more peptides than the Varian C8 SPE cartridges (data not
shown). However, in the eluted fraction of both cartridges,
a ‘brown substance’ that co-purified with the endogenous
peptide fraction was present. This substance was partially
removed by further processing the sample with ethyl
acetate, as reported previously [17]. Partial removal of this
unknown substance led to an approximate two fold
increase in peptide identification (data not shown).
When urine samples were not reduced or alkylated,
very few peptides with cysteine (cys) residues were de-
tected (data not shown). This was unexpected since the
frequency of cys in the IPI 3.71 human database is 3%,
and the frequency of cysteine in peptides that were
detected in various published urine proteomes was also
3% [18,19]. By examining urine peptidomes from the
literature, it was noted that they had an unusually low
level of cysteines [20-23]. This finding led us to examine
this anomaly in greater detail. After analyzing the cys
content of various other peptidomes, it became readily
apparent that those studies that reduced and alkylated
their fluids prior to peptide extraction [24,25] had higher
cys content than those that did not [20-23]. This finding
was of no surprise to us and the exclusion of cysteine-
containing peptides from the urine peptidome by not re-
ducing or alkylating may be detrimental. Many biologically
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sulfide bridges which not only determine the functional
structure of the proteins but also often protect them from
proteolysis. Additionally, some of the antimicrobial en-
dogenous peptides such as defensins, are bonded into spe-
cific structures via disulfide bridges [24]. In this study, we
were able to identify several cysteine-containing peptides
that have known biological importance such as the granu-
lins, uteroglobin and hepcidin (Additional file 1: S1A and
S1B). The benefit of reduction and alkylation of samples in
the identification of endogenous peptides has also been
reported elsewhere [26]. Figure 1 depicts the final sample
preparation procedure that was followed for deciphering
the urine peptidome, based on the optimization steps out-
lined above.
Optimization of bioinformatics for urine peptidome
identification
Once the sample preparation was optimized, the ability of
the GPM search engine to detect endogenous peptidesUrine sa
















Figure 1 Outline of experimental workflow (peptidomic analysis). The
followed by strong cation exchange and reverse-phase chromatography co
data analysis.was examined. The same concatenated forward-random
database, as well as the same .mgf files generated from
extract_msn was used. The resultant .xml files were ana-
lyzed in Scaffold to calculate and set the false-discovery
rate (FDR) at 1%. The effect of the inclusion or exclusion
of oxidized proline (oxP) in terms of the total number of
peptides and proteins identified was also examined. These
results showed that GPM did not show a large difference
in the number of proteins and peptides identified with the
inclusion or exclusions of oxP. For example, without
oxidized proline, 739 proteins and 4539 peptides were
identified. With oxidized proline, 713 proteins and 4607
peptides were identified. Based on the above results, the
final bioinformatic searches were performed with GPM
and the following modifications: oxP and oxidized methio-
nine (oxM).
Deciphering the ovarian cancer urine peptidome
In conventional bottom-up proteomic experiments, pro-

















workflow consisted of an optimized sample processing procedure,
upled online to an LTQ-Orbitrap mass spectrometer, and subsequent
(A)
(B)
Figure 2 Overlap of the total proteins (A) and peptides (B)
identified in control (n = 6) and ovarian cancer (OvCa) (n = 6)
samples. Each sample was processed in triplicate. Over 300 unique
proteins were found in the OvCa urine and over 3100 peptides were
unique to OvCa compared to healthy controls.
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C-terminal basic amino acids that are protonated under
acidic conditions. These protonated amino acids assist in
peptide fragmentation and subsequent bioinformatic
identification. Since the protease(s) responsible for the
production of endogenous urine peptides are unknown,
the data required the use of no enzyme specificity ([X]|
[X]), and very few variable modifications (to limit database
size). Sparse use of variable modifications is disadvanta-
geous to endogenous peptide identification as many of
these peptides are known to be modified [26]. Despite
these limitations, from the 6 OvCa and 6 control urine
specimens examined in this study, we were able to identify
4607 unique peptides, including known endogenous urine
peptides, originating from 713 protein precursors (Figure 2,
Additional file 1: S1 and S2). The Scaffold file used in this
study can be found in Supplementary Information S2 and
a free Scaffold 2.06 viewer can be downloaded from http://
www.peptideatlas.org/PASS/PASS00204 (follow link ftp://
PASS00204:ZH3882n@ftp.peptideatlas.org/). Figure 2 (A)
and (B) displays the overlap between the proteins and
unique peptides identified in the control and OvCa sam-
ples, respectively. The control samples consisted of 380
proteins and 1452 unique peptides, while the OvCa cohort
consisted of 514 proteins and 3646 unique peptides. A
large fraction of the peptides were uniquely identified in
the OvCa samples and this could have possibly resulted
from reported higher protease activity in malignant cells
[4-9]. The list of 333 unique proteins to OvCa is provided
in Additional file 2: S3A. The list of 3155 unique peptides
identified solely from OvCa specimensare provided in
Additional file 2: S3B.
The results of the individual sample analysis yielded be-
tween 268 to 1933 unique peptides and 84–374 proteins
per specimen (Table 1). To our knowledge, this repository
represents the largest collection of endogenous urinary
peptides to date. Most importantly, it presents the only
OvCa urine peptidome in the literature [27].
It should be noted that all urine samples were proc-
essed and analyzed in triplicate. The repeatability of our
methodology is shown in Figure 3, which highlights the
overlap at the protein and peptide level for all OvCa and
healthy control urine samples that were independently
processed in triplicate. On average, 69-76% reproducibil-
ity was observed at the protein level and 58-63% was ob-
served at the peptide level for both cases and controls.
These values were based on protein and/or peptides list
from pairs of technical replicates. Our results are consist-
ent with the literature showing higher repeatability and
reproducibility for proteins than for peptides [28]. This
highlights the importance of processing each sample in
triplicate or more to truly decipher as much of the pepti-
dome as possible. Our results indicate that there is a
large inter-individual variability in peptide/protein contentbetween OvCa and control urine samples (Table 1). Since
we performed triplicate analysis of each sample (Figure 3),
we can be confident that this variability is due to physio-
logical/biological differences in urine content rather than
the technical aspects of sample preparation. In a recent
study of variability of the normal urinary proteome by
Nagaraj et al., it was shown that intrapersonal and inter-
personal variability contributed 46% and 47% to total vari-
ability, respectively [29]. Overall variability is also greater
in OvCa patients than controls and this could be a result
of differences in medical conditions of the OvCa patients.
Table 1 Number (triplicate analysis) of proteins and peptides found in urine of 6 ovarian cancer patients (OvCa) and 6
healthy controls
Sample Proteins Standard deviation Peptides Standard deviation
OvCa_1 192 8 1005 34
OvCa_2 84 18 313 51
OvCa_3 103 2 367 4
OvCa_4 374 15 1933 53
OvCa_5 118 21 482 52
OvCa_6 116 9 659 6
Control_1 125 17 382 81
Control_2 121 3 377 10
Control_3 91 13 268 38
Control_4 171 7 526 122
Control_5 223 4 756 22
Control_6 109 3 357 39
All 713 4607
Number of proteins and peptides are the sum of triplicate analysis with a false-discovery rate (FDR) of 1%. The average number of proteins identified in the OvCa
and control samples are 165 and 140, whereas the average number of unique peptides are 793 and 444, respectively. “All” represents the total number of non-







































Figure 3 Protein and peptide repeatability. To assess repeatability, we examined the overlapping fraction of identified protein or peptide in
pairs of biological replicates. The percentage of repeatability for proteins (open diamond) vs peptides (closed box) for each sample is shown.
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variability in peptide identifications in OvCa urine suits the
hypothesis which states that malignant cells have higher
metabolic and protease activity than normal cells [4-9]
Comparison of ovarian urine proteome and peptidome to
other publications
Fredolini et al. compared the proteome of 20 serum sam-
ples from patients with early-stage epithelial OvCa with 20
samples from patients diagnosed with benign gynecological
conditions [12]. A total of 59 proteins were found to be
over-expressed in OvCa compared to the control cohort.
Out of these 59 proteins, our study identified 16 of these
proteins (which represents 27% overlap). Additional file 3:
S4 contains the list of overlapping proteins for each publi-
cation examined here. It should be noted that the objective
of our study was not to decipher the proteome of urine
OvCa and thus, it is not surprising that more proteins were
not overlapping with Fredolini et al. Another study, by
Lopez et al., looked at the serum proteome of 110 healthy
individuals and 453 patients with OvCa (including stages I-
IV) [30]. The authors identified 160 proteins that were
overexpressed in ovarian cancer compared to healthy con-
trols. Among the 160 proteins, our study identified 15 of
these candidates, yielding an overlap of 9.4%. Three pro-
teins (Fibrinogen beta chain, Keratin, type I cytoskeletal 9
and Transgelin-2) were identified by all 3 studies. A recent
publication has implicated transgelin-2 to have a role in
the development and progression of brain metastases from
gynecological malignancies [31]. Lastly, Siwy et al. pub-
lished a paper examining the human urinary peptide data-
base [27]. This consisted of 114 proteins and 787 peptides.
It should be mentioned that OvCa was not included in the
list of diseases examined. Nonetheless, our study identified
63 of these proteins and 283 peptides.
Lack of collagen peptides
The most notable difference between peptides identified
in this study and others is the lack of identified collagen
peptides. On a percentage basis, collagen peptides made
up 9% of the total identified peptides in our study as com-
pared to 87% [32], and 74% [20] in other studies, respect-
ively. These finding led Good et al. to state that “Collagen
fragments, especially fragments of collagen alpha-1 (I)
chain, appear to be the major constituents of urinary pep-
tides” [20]. We were unable to determine the root cause
for this large discrepancy. One possible reason for the
similarity in collagen frequency in the previously men-
tioned studies could be that similar methods were used
(same research group). We noted also that these studies
used several variable modifications, including oxP, in the
bioinformatic processing of their data. It has been shown
that proline residues are oxidized in collagen [33], and a
review of these studies demonstrated the identification ofpeptides with oxP. When we processed our data with
Mascot (another search engine) and included oxP and
oxM (to make the bioinformatic processing of our data
more similar to other studies) we found collagen peptide
content to be 7%. However, despite mimicking the bio-
informatics to the previous studies, we were unable to
identify such a high percentage of collagen peptides in our
present study.
Leucine-rich alpha-2-glycoprotein: a potential ovarian
cancer biomarker
One of the highly promising biomarkers that emerged
from this study was Leucine-rich alpha-2-glycoprotein
(LRG1). Interestingly, with the exception of one peptide
being identified in Control sample #3 (GKDLLLPQPD
LRY), LRG1 was detected only in OvCa samples (present
in all 6 OvCa urine specimens). Figure 4 displays a sche-
matic representation of the LRG1 protein and the
highlighted areas reveal the peptides that were identified
per sample. It is evident that no single identical peptide
was consistently identified in all samples (OvCa and con-
trol). A large number of these peptides in OvCa samples
appear to be generated by exopeptidase activity of a ‘com-
mon peptide core’ creating a ladder like effect (data not
shown). Similar findings have been seen in other pepti-
domes deciphered to date [34,35]. The LRG1 protein has
previously been suggested to be an OvCa biomarker. First,
it was identified in OvCa ascites fluid by our group [36]. In
addition, it was found to be upregulated in the sera of
OvCa patients by Chen et al. using 2-dimensional gel elec-
trophoresis followed by MALDI-MS identification [37]. It
was also identified by another group based on a serum-
peptidomics approach using nanoparticles [12]. These dis-
covery results showing LRG1 as a potential novel bio-
marker for OvCa were verified using an immunoassay
(ELISA) on serum and tissues of affected women [38]. In
the latter study, a statistically significant two-fold increase
in serum LRG1 was found compared to healthy controls.
Such differential results were also obtained when compar-
ing mRNA levels in ovarian tissue samples. However, one
limitation of this approach was that the area under the
curve (AUC) for LRG1 and the AUC of the combined
markers (LRG1 + CA125) were not statistically different
from the AUC of CA125 alone. Recently, LRG1 was found
to be enriched in the urine of patients with appendicitis
[39], as well as the serum of individuals with lung cancer
[40], and heart failure [41]. It has also been suggested as a
biomarker of ulcerative colitis [42]. These results demon-
strate elevated expression of LRG1 protein in several disor-
ders, and therefore LRG1 protein levels may not be
suitable for use as a specific diagnostic marker of OvCa.
On the other hand, unique LRG1 endogenous peptides
found in the urine of ovarian cancer patients may hold













Figure 4 Peptides identified in the LRG1 protein. A schematic representation of the LRG1 protein and the highlighted areas reveal the peptides
identified per sample.
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cell adhesion [43,44].
Further examination of peptides identified from the
LRG1 protein showed that all OvCa samples contain pep-
tides from the same core region with the presence of Argin-
ine (Arg) at positions 191 and 209 in the sequences.
Therefore, treatment of the OvCa samples with trypsin
could produce the common proteotyptic peptide 192TLDL
GENQLETLPPDLLR209 which can be used to quantitate
the level of LRG1 peptide in other, independent urine sam-
ple cohorts. Future studies will focus on quantitation of the
tryptic LRG1 peptide TLDLGENQLETLPPDLLR in OvCa
urine samples.
Conclusions
In this study, we developed an optimized procedure to
identify endogenous peptides in urine from OvCa pa-
tients and healthy individuals. Using this strategy, a large
number of endogenous urine peptides (>4600 peptides)
were identified, representing the largest repository of
urine peptidomics to date. This database contains valu-
able information that will enable future researchers to
identify novel OvCa peptide biomarkers, as over 3000
unique peptides were identified solely in OvCa urines
compared to healthy control urine specimens. The high
abundance of LRG1 peptides in the OvCa sample co-
hort, and near absence in controls, in conjunction with
the previous identification of LRG1 protein in various
diseases, suggest that future validation of LRG1 peptides
by using quantitative selected reaction monitoring assays
in larger numbers of urines is warranted.
Methods
Sample collection
Second morning urine samples from 6 late-stage, serous
ovarian cancer patients and 6 age-matched healthy women
were obtained after written informed consent and institu-
tional ethics board approval. After collection, samples werealiquoted and immediately frozen at −20°C until further
analysis. One aliquot was used to perform urinalysis dip-
stick testing (Clinitek Atlas), and urine creatinine measure-
ments using clinical laboratory analyzers (Abbott
Architect). Histological examination of the tumor tissue
samples obtained at surgery classified all six patients as
having a serous subtype (stage IV). Statistical analysis of
the control group (n = 6) and OvCa patients (n = 6) indi-
cated that the two groups were not significantly different
in terms of age.
Sample preparation
Urine samples were thawed at 37°C and vortexed to re-
suspend any precipitate. All specimens (cases and controls)
were processed in triplicate and in parallel, using the same
lot of reagents and columns, to minimize variability or bias
in sample preparation. The samples were centrifuged at
2000 g. Urine volumes were normalized with respect to
135 mmol of creatinine per sample (approximately 10–
20 mL per individual). The pH of the urines was adjusted
to 8.0 by the addition of solid ammonium bicarbonate. A
final concentration of 2 mmol/L (mM) of dithiothreitol
(DTT) from Sigma-Aldrich was added and the samples in-
cubated at room temperature for 30 min before the
addition of a final concentration of 4 mM iodoacetamide
(Sigma-Aldrich). The urine was then concentrated with
Vivaspin 20 mL 10 kDa cutoff membranes (Sartorius
Stedim Biotech), according to the manufacturer’s instruc-
tions (concentrators were flushed with 20 mL water prior
to use). The concentrator flow through was acidified by
drop wise addition of formic acid to pH 4.0. Following the
molecular weight enrichment for endogenous peptides, the
samples were passed through a hydrophilic-lipophilic-
balanced reversed-phase cartridge (Oasis HLB). The
cartridge (1 cc (30 mg); Waters cat# WAT094225) was
pre-equilibrated with 1 mL 90% acetonitrile (ACN), 0.1%
formic acid and 0.02% TFA. The cartridge was washed
with 15 mL buffer A (5% ACN, 0.1% formic acid and
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ridge was washed with 15 mL of buffer A. Peptides were
eluted by adding 700 uL of 60% ACN, 0.1% formic acid,
0.02% TFA. The eluted fraction was mixed with an equal
volume of ethyl acetate and centrifuged at 17 000 g for
5 minutes. The upper layer was discarded and the sample
was reduced to a volume of approximately 200 uL via
speed vac.
Strong cation exchange chromatography
An equal volume of mobile phase A (0.26 M formic acid
in 5% ACN) was added to the sample and injected into a
PolySULFOETHYL A column with a 200-Å pore size
and diameter of 5 μm (The Nest Group, Inc) containing
a hydrophilic, anionic polymer (poly-2-sulfethyl asparta-
mide). A 1 hour separation was performed on an HPLC
system (Agilent 1100) using a mobile phase B containing
0.26 M formic acid in 5% ACN and 1 M ammonium for-
mate. The eluate was monitored at a wavelength of
280 nm. Seven fractions per sample were collected at a
flow rate of 200 μL/min.
Mass spectrometry
The fractions were desalted by using an Omix C18 pipette
tip (Varian) and eluted in 5 μL of buffer B (70% aceto-
nitrile, 0.1% formic acid). After elution, 80 μL of buffer A
(0.1% formic acid) was added to each sample and 40 μL
were loaded onto a 2-cm C18 trap column, packed with
Varian Pursuit (5 μm C18), using the EASY-nLC system
(Proxeon Biosystems). Peptides were eluted from the trap
column onto a resolving 5-cm analytical C18 column
packed with Varian Pursuit (3 μm C18) with an 8 μm tip
(New Objective). This LC setup was coupled online to an
LTQ-Orbitrap XL (Thermo Fisher Scientific) mass spec-
trometer using a nanoelectrospray ionization source
(Proxeon Biosystems). Each fraction underwent a 54-min
gradient, and eluted peptides were subjected to 1 full scan
(350–2000 m/z) in the Orbitrap at 60 000 resolution,
followed by top 6 data-dependent MS/MS scans in the lin-
ear ion trap. With the use of charge-state screening and
preview mode, unassigned charge states were rejected.
Data analysis
Raw files were used to generate Mascot Generic Files
(MGF) through extract_msn on Mascot Daemon (ver-
sion 2.2.2). Once generated, MGFs were searched with
X!Tandem (Global Proteome Machine Manager; version
2006.06.01) to confer peptide identifications. Searches
were conducted against the non-redundant Human IPI
database (v.3.71) which contains a total of 173,490 for-
ward and randomized protein sequences and using the
following parameters for GPM: no enzyme ([X]|[X])
cleavages, 50 missed cleavage sites allowed, 7 ppm pre-
cursor ion mass tolerance, 0.4 Da fragment ion masstolerance, fixed modifications of carbamidomethylation of
cysteines, and variable modification of oxidation of methi-
onines (oxM) and/or prolines (oxP). The X!Tandem (XML
files) were then integrated through the Scaffold 2 software
(version 2.06; Proteome Software Inc., Portland, Oregon).
False-discovery rates (FDR) were calculated as the number
of peptides identified by the randomized reverse database
divided by the total number of identified peptides. To
achieve a peptide FDR of 1%, X!Tandem –Log(Expect-
Scores) peptide scores of 2.2 or greater were accepted.
Additional files
Additional file 1: Peptide and protein report.
Additional file 2: List of proteins and peptides detected solely in
OvCa urine.
Additional file 3: List of overlapping proteins with other
publications.
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